中国药业2025，Vol.34Issue(15)：1-14,14.DOI:10.3969/j.issn.1006-4931.2025.15.001
非奈利酮临床应用与药学监护中国专家共识
Chinese Expert Consensus on the Clinical Application and Pharmaceutical Care of Finerenone
摘要
Abstract
Objective To promote the standardized utilization of the novel non-steroidal mineralocorticoid receptor antagonist(finerenone)in clinical practice.Methods Based on evidence-based data and real-world clinical experience,32 experts from diverse disciplines including clinical pharmacy,nephrology,and endocrinology used the Delphi approach to formulate this consensus.Through two rounds of comprehensive expert opinion surveys and three rounds of discussions,followed by anonymous voting(consensus was defined as more than 80%of experts reaching agreement)and open solicitation of expert insights,the Chinese Expert Consensus on the Clinical Application and Pharmaceutical Care of Finerenone was ultimately formulated.Results From the dimension of clinical application and pharmaceutical care,this consensus has formed 14 recommendations concerning the target patient population,key points of pharmaceutical care,and drug-drug interactions of finerenone.Conclusion Based on existing evidence from evidence-based medicine and clinical experience,this consensus has formed the clinical indications,timings of medication,dosing regimens,drug-drug interactions,monitoring strategies and corresponding countermeasures for adverse reactions of finerenone.Moreover,it provides detailed recommendations and expert advice,thereby furnishing a reference for the rational drug use and pharmaceutical care of finerenone in clinical practice.关键词
2型糖尿病/慢性肾脏病/非奈利酮/药学监护/专家共识Key words
type 2 diabetes mellitus/chronic kidney disease/finerenone/pharmaceutical care/expert consensus分类
医药卫生引用本文复制引用
《非奈利酮临床应用与药学监护中国专家共识》专家组,朱万虎,张剑萍,郭澄..非奈利酮临床应用与药学监护中国专家共识[J].中国药业,2025,34(15):1-14,14.基金项目
国家重点研发计划子课题[2020YFC2005502] （）
上海市药学会药学服务青年创新项目[SPAYXFW2025B04]. （）
